Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

78.97USD
11:45am EDT
Change (% chg)

$-0.75 (-0.94%)
Prev Close
$79.72
Open
$78.87
Day's High
$79.72
Day's Low
$78.85
Volume
388,004
Avg. Vol
1,300,695
52-wk High
$89.07
52-wk Low
$73.70

Select another date:

Wed, Apr 4 2018

BRIEF-Lilly And Sigilon Therapeutics Announce Strategic Collaboration To Develop Encapsulated Cell Therapies

* LILLY AND SIGILON THERAPEUTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP ENCAPSULATED CELL THERAPIES FOR THE TREATMENT OF TYPE 1 DIABETES

BRIEF-Tasly Pharma's Unit Signs Licensing Agreement On Diabetes Medicine With Eli Lilly

* SAYS UNIT SIGNS LICENSING AGREEMENT ON DIABETES MEDICINE WITH ELI LILLY Source text in Chinese: https://bit.ly/2EfkbCp Further company coverage: (Reporting by Hong Kong newsroom)

CVS appoints former Eli Lilly CFO as president of PBM business

March 20 Drugstore operator chain CVS Health Corp said it had hired former Eli Lilly Chief Financial Officer Derica Rice as the president of its pharmacy benefit management (PBM) business.

BRIEF-Eli Lilly CEO David Ricks' Total Compensation For 2017 Was $15.8 Mln

* ELI LILLY AND CO CEO DAVID RICKS' TOTAL COMPENSATION FOR 2017 WAS $15.8 MILLION - SEC FILING Source text (http://bit.ly/2HN2BHI) Further company coverage:

BRIEF-Eli Lilly Says New Data Show Trulicity Combo Treatment Improves Blood Sugar Control In Type 2 Diabetes Patients

* ELI LILLY SAYS NEW DATA SHOW TRULICITY (DULAGLUTIDE) IN COMBINATION WITH SGLT-2 INHIBITOR IMPROVES BLOOD SUGAR CONTROL IN PEOPLE WITH TYPE 2 DIABETES Source text for Eikon: Further company coverage:

BRIEF-Eli Lilly Says CEO David Ricks' FY 2017 Total Compensation Was $15.8 Mln

* ELI LILLY AND CO SAYS CHAIRMAN AND CEO DAVID RICKS' FY 2017 TOTAL COMPENSATION WAS $15.8 MILLION

Novo Nordisk gets nod from U.S. drug purchaser for new diabetes hope

COPENHAGEN Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly's Trulicity.

Novo Nordisk gets nod from U.S. drug purchaser for new diabetes hope

COPENHAGEN, Feb 21 Insulin maker Novo Nordisk said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly's Trulicity.

BRIEF-Adocia Files Additional Arbitration Claims Against Eli Lilly & Company​

* ‍ADOCIA FILES ADDITIONAL ARBITRATION CLAIMS AGAINST ELI LILLY & COMPANY​

BRIEF-Eli Lilly plans to deploy around $9 bln of global cash

* SEES 2018 EFFECTIVE TAX RATE OF 18%, DOWN FROM PREVIOUS NON-GAAP EXPECTATION OF 21.5%

Select another date: